InterOcean Capital LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 17.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,602 shares of the company’s stock after purchasing an additional 966 shares during the period. InterOcean Capital LLC’s holdings in Merck & Co., Inc. were worth $508,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of MRK. BlackRock Inc. raised its position in Merck & Co., Inc. by 2.9% in the first quarter. BlackRock Inc. now owns 196,345,328 shares of the company’s stock valued at $15,106,811,000 after purchasing an additional 5,562,103 shares during the period. State Street Corp increased its position in shares of Merck & Co., Inc. by 1.0% during the 4th quarter. State Street Corp now owns 116,493,884 shares of the company’s stock worth $10,665,449,000 after purchasing an additional 1,196,724 shares during the last quarter. Geode Capital Management LLC raised its holdings in Merck & Co., Inc. by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 39,980,410 shares of the company’s stock valued at $3,629,567,000 after buying an additional 685,744 shares during the period. Capital International Investors raised its holdings in Merck & Co., Inc. by 2.7% in the 4th quarter. Capital International Investors now owns 39,628,116 shares of the company’s stock valued at $3,604,177,000 after buying an additional 1,034,782 shares during the period. Finally, Janus Henderson Group PLC lifted its position in Merck & Co., Inc. by 16.5% in the fourth quarter. Janus Henderson Group PLC now owns 28,954,215 shares of the company’s stock valued at $2,633,372,000 after buying an additional 4,108,756 shares during the last quarter. Institutional investors own 75.25% of the company’s stock.
A number of equities research analysts have recently issued reports on MRK shares. Mizuho reissued a “buy” rating on shares of Merck & Co., Inc. in a research note on Wednesday, February 5th. Argus dropped their target price on shares of Merck & Co., Inc. from $105.00 to $95.00 and set a “buy” rating for the company in a report on Tuesday, March 24th. Morgan Stanley decreased their price target on Merck & Co., Inc. from $97.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, April 2nd. SVB Leerink lowered their price target on Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, April 29th. Finally, Royal Bank of Canada cut their price objective on Merck & Co., Inc. from $92.00 to $89.00 and set a “sector perform” rating on the stock in a report on Wednesday, April 1st. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $93.60.
In other Merck & Co., Inc. news, Director Wendell P. Weeks sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total transaction of $380,100.00. Following the completion of the transaction, the director now owns 5,100 shares in the company, valued at approximately $387,702. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.28% of the stock is owned by insiders.
NYSE MRK traded down $0.18 during trading hours on Friday, hitting $76.37. 6,046,385 shares of the company were exchanged, compared to its average volume of 10,529,766. The company has a 50 day moving average of $79.51 and a two-hundred day moving average of $83.36. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a 52-week low of $65.25 and a 52-week high of $92.64. The firm has a market cap of $193.22 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 2.12 and a beta of 0.50.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $1.50 EPS for the quarter, topping the Zacks’ consensus estimate of $1.34 by $0.16. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The business had revenue of $12.06 billion during the quarter, compared to the consensus estimate of $11.46 billion. During the same period in the previous year, the company posted $1.22 earnings per share. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, equities research analysts predict that Merck & Co., Inc. will post 5.31 EPS for the current year.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Further Reading: Diluted Earnings Per Share
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.